Opportunity Overview
Because ALT-0701 is already FDA approved for other applications,
and the pharmacolgy and toxicology is well documented, AltruGen
has the opportunity to initiate Phase II clinical trials immediately.
Although RTIF is a poorly understood and there is no optimal
treatment, as many as 40% of radiation therapy patients suffer
from the condition. As many as 50% of all cancer patients
will undergo radiation therapy and because RTIF can last
for months and even years, it poses a significant quality
of life issue.
Moreover, as RTIF is the major dose-limiting
factor in radiation therapy, it limits the duration and effectiveness
of the treatment. AltruGen's ALT-0701 has the unique ability
to sensitize radiation-resistent tumors cells, while preventing
RTIF.
|
